Abstract
Janus kinase-2 (JAK2) is a non-receptor tyrosine kinase that serves key roles as the intracellular signaling effector of the cytokine receptor, such as mediating effects of leptin, erythropoietin, interferon, and growth hormone. A lot of molecular underlying mechanisms of JAK2 participation are known, however, additional signaling mechanisms of its activation, regulation, and pleiotropic signaling roles are still being explored. Here, we review the current knowledge of JAK2-mediated cellular signaling at the molecular level. In the beginning, we will focus on the recent advances in JAK2 activation and regulation. A part of our review focuses on the JAK2 involvement in various diseases/conditions. Recent advances highlight the molecular regulatory mechanisms utilized by the JAK2 signaling, thus, enabling to consider alternative therapeutic strategies to treat various diseases/conditions mediated by JAK2 by using it as a therapeutic target.
Keywords: Jak2, STAT, protein kinases, hormones, intracellular signaling, cytokine receptor.
Current Molecular Medicine
Title:JAK2-mediated Intracellular Signaling
Volume: 21 Issue: 5
Author(s): Mentor Sopjani*, Rifat Morina, Valdet Uka, Nguyen Thi Xuan and Miribane Dërmaku-Sopjani*
Affiliation:
- Faculty of Medicine, University of Prishtina, 10 000, Prishtine,Kosova
- Faculty of Natural Sciences and Mathematics, University of Prishtina, 10 000, Prishtinë,Kosova
Keywords: Jak2, STAT, protein kinases, hormones, intracellular signaling, cytokine receptor.
Abstract: Janus kinase-2 (JAK2) is a non-receptor tyrosine kinase that serves key roles as the intracellular signaling effector of the cytokine receptor, such as mediating effects of leptin, erythropoietin, interferon, and growth hormone. A lot of molecular underlying mechanisms of JAK2 participation are known, however, additional signaling mechanisms of its activation, regulation, and pleiotropic signaling roles are still being explored. Here, we review the current knowledge of JAK2-mediated cellular signaling at the molecular level. In the beginning, we will focus on the recent advances in JAK2 activation and regulation. A part of our review focuses on the JAK2 involvement in various diseases/conditions. Recent advances highlight the molecular regulatory mechanisms utilized by the JAK2 signaling, thus, enabling to consider alternative therapeutic strategies to treat various diseases/conditions mediated by JAK2 by using it as a therapeutic target.
Export Options
About this article
Cite this article as:
Sopjani Mentor *, Morina Rifat , Uka Valdet , Xuan Thi Nguyen and Dërmaku-Sopjani Miribane *, JAK2-mediated Intracellular Signaling, Current Molecular Medicine 2021; 21 (5) . https://dx.doi.org/10.2174/1566524020666201015144702
DOI https://dx.doi.org/10.2174/1566524020666201015144702 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study
Current Drug Targets Color-Coded Fluorescent Protein Imaging of Angiogenesis: The AngioMouse® Models
Current Pharmaceutical Design Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry Cytokine Therapeutics for the Treatment of Sepsis: Why has Nothing Worked?
Current Pharmaceutical Design Other Future Targeting Therapy Beyond TNF-α Inhibitor in Patients with Spondyloarthropathy
Current Rheumatology Reviews Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Left Atrial Appendage Closure -The WATCHMAN Device
Current Cardiology Reviews Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism RNA Interference: New Therapeutics in Allergic Diseases
Current Gene Therapy Obesity and Insulin Resistance: Associations with Chronic Inflammation, Genetic and Epigenetic Factors
Current Medicinal Chemistry Metabolic Fate of Endocannabinoids
Current Neuropharmacology Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Pathogenesis of Chronic Lymphocytic Leukemia
Current Molecular Medicine Role of Cation-Chloride-Cotransporters (CCC) in Pain and Hyperalgesia
Current Topics in Medicinal Chemistry